Big Pharma Split Corp.
Big Pharma Split Corp. (PRM.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
PRM.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsBig Pharma Split Corp. trailing twelve-month (TTM) revenue is $0.00B, a decrease of 21.38% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2017 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -21.38% |
| 2024-12-31 | $0.00B | +$0.00B | +493.09% |
| 2023-12-31 | $0.00B | -$0.00B | -92.06% |
| 2022-12-31 | $0.00B | -$0.00B | -26.74% |
| 2021-12-31 | $0.01B | +$0.00B | +73.95% |
| 2020-12-31 | $0.00B | +$0.00B | +26.57% |
| 2019-12-31 | $0.00B | -$0.00B | -24.69% |
| 2018-12-31 | $0.00B | +$0.00B | +693.91% |
| 2017-12-31 | $0.00B | — | — |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Big Pharma Split Corp. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Big Pharma Split Corp. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Big Pharma Split Corp.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
PRM.TO revenue · 4 questionsPRM.TO's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 21.38% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Big Pharma Split Corp. SEC filings · GAAP · Big Pharma Split Corp. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026